Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

1.

siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo.

Khairuddin N, Gantier MP, Blake SJ, Wu SY, Behlke MA, Williams BR, McMillan NA.

Immunol Cell Biol. 2012 Feb;90(2):187-96. doi: 10.1038/icb.2011.19. Epub 2011 Mar 22.

PMID:
21423261
[PubMed - indexed for MEDLINE]
2.

[RNA interference: biogenesis molecular mechanisms and its applications in cervical cancer].

Peralta-Zaragoza O, Bermúdez-Morales VH, Madrid-Marina V.

Rev Invest Clin. 2010 Jan-Feb;62(1):63-80. Review. Spanish.

PMID:
20415061
[PubMed - indexed for MEDLINE]
3.

HPV: from infection to cancer.

Stanley MA, Pett MR, Coleman N.

Biochem Soc Trans. 2007 Dec;35(Pt 6):1456-60. Review.

PMID:
18031245
[PubMed - indexed for MEDLINE]
4.

[Molecular basis of cervical carcinogenesis by high-risk human papillomaviruses].

Yugawa T, Kiyono T.

Uirusu. 2008 Dec;58(2):141-54. Review. Japanese.

PMID:
19374192
[PubMed - indexed for MEDLINE]
Free Article
5.

Deciphering the code of innate immunity recognition of siRNAs.

Sioud M.

Methods Mol Biol. 2009;487:41-59. doi: 10.1007/978-1-60327-547-7_2. Review.

PMID:
19301641
[PubMed - indexed for MEDLINE]
6.

Advances in the development of therapeutic nucleic acids against cervical cancer.

DiPaolo JA, Alvarez-Salas LM.

Expert Opin Biol Ther. 2004 Aug;4(8):1251-64. Review.

PMID:
15268660
[PubMed - indexed for MEDLINE]
7.

Genetically modified cellular vaccines for therapy of human papilloma virus type 16 (HPV 16)-associated tumours.

Bubenik J.

Curr Cancer Drug Targets. 2008 May;8(3):180-6. Review.

PMID:
18473731
[PubMed - indexed for MEDLINE]
8.

siRNA and isRNA: two edges of one sword.

Schlee M, Hornung V, Hartmann G.

Mol Ther. 2006 Oct;14(4):463-70. Epub 2006 Jul 31. Review.

PMID:
16877044
[PubMed - indexed for MEDLINE]
9.

Molecular approaches to cervical cancer therapy.

Alvarez-Salas LM, DiPaolo JA.

Curr Drug Discov Technol. 2007 Oct;4(3):208-19. Review.

PMID:
17986003
[PubMed - indexed for MEDLINE]
10.

Strategies for designing and validating immunostimulatory siRNAs.

Gantier MP.

Methods Mol Biol. 2013;942:179-91. doi: 10.1007/978-1-62703-119-6_10. Review.

PMID:
23027052
[PubMed - indexed for MEDLINE]
11.

Recent advances in understanding of the immunological off-target effects of siRNA.

Olejniczak M, Polak K, Galka-Marciniak P, Krzyzosiak WJ.

Curr Gene Ther. 2011 Dec;11(6):532-43. Review.

PMID:
22023470
[PubMed - indexed for MEDLINE]
12.

siRNA and cancer immunotherapy.

Ghafouri-Fard S, Ghafouri-Fard S.

Immunotherapy. 2012 Sep;4(9):907-17. doi: 10.2217/imt.12.87. Review.

PMID:
23046235
[PubMed - indexed for MEDLINE]
13.

Advancements in the field of intravaginal siRNA delivery.

Yang S, Chen Y, Ahmadie R, Ho EA.

J Control Release. 2013 Apr 10;167(1):29-39. doi: 10.1016/j.jconrel.2012.12.023. Epub 2013 Jan 5. Review.

PMID:
23298612
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk